Skip to content
Friday 14 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,750.11
-0.21%
DAX
26,440.31
+0.53%
CAC 40
8,636.80
-0.16%
STOXX 50
6,539.59
-0.09%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Wednesday 03 July 2024 10:59 am  |  Updated:  Wednesday 03 July 2024 1:18 pm

UK less ready for next pandemic than before Covid – Oxford vaccinologist

By: Ali Lyon

Add as a preferred source on Google
Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
Astrazeneca shareholders have questioned the possible merger

The UK’s state apparatus is less prepared to deal with a pandemic today than it was before Covid, one of the vaccinologists in charge of the Oxford Astrazeneca vaccine rollout has warned.

Dr. Adam Ritchie of the University of Oxford, who played an integral role in developing the innovative biomedical technology that enabled the rapid scaling up of the UK-made vaccine across countries and continents, said the mothballing of an Oxfordshire-based vaccine manufacturing centre has set the country back in its preparedness to deal with the next pandemic.

Speaking to Morning Wire after his technology was nominated for the Royal Academy of Engineering’s (Raeng) MacRobert Award, Dr. Ritchie said: “It is super fair to say that the state apparatus is no better equipped [to deal with a future pandemic breakout].

“And in fact, amazingly, we may have gone backwards. Because, pre-pandemic, there was something being set up led by the government called the Vaccine Manufacturing Innovation Centre (VMIC) in South Oxfordshire.

“That was going to be built and it was going to have its own manufacturing facility to make potentially millions of doses.

“And I guess because [during Covid] things went well from a vaccine perspective, the government sold it and then it was mothballed, which was not a good thing.”

The £200m VMIC was built in 2017 as a non-profit intended to combine vaccine research and manufacturing.

Read more

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

But when the Covid outbreak struck, the centre wasn’t yet fully functional, leading the organisations responsible for developing the vaccine to favour other centres at Oxford University and elsewhere for their work.

It was then sold to US firm Catalent in 2022 before it was fully complete.

Dr. Ritchie added: “You obviously can’t just have a white elephant sitting there waiting for something to happen, but you also need a bit of a core state function.

“That said, from a technical perspective, we’re stronger. Crisis is the mother of innovation, and we learnt how to do things in year that ordinarily would take 5 or 10.”

Dr. Ritchie’s comments coincided with an uptick in Coronavirus cases, with talk of a “summer Covid wave” growing with the news that a new group of variants had been discovered.

He made them after he and his team, along with Astrazeneca, were nominated for the the award that is widely viewed as the most coveted in engineering, drawing comparisons to the Nobel Prize.

Commenting on the nomination, judge Alison Vincent CBE, said: “The manufacturing and scale-up of the Oxford Astrazeneca vaccine was a truly amazing collaboration. It was a multi-partner, multi-country project which delivered a vaccine in a much quicker time and at a lower cost than what we’ve seen before.”

Read more

Why did Pinterest choose Oxford Street for its new HQ?

Gregory Owens and Sadiq Khan, London Mayor, stand smiling in a gallery with various framed images.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

People & Organisations

  • Astrazeneca
  • catalent
  • Macrobert Award
  • nobel prize
  • royal academy of engineering
  • University of oxford
  • Vaccine

Related Topics

  • NHS
  • Pharmaceuticals
  • Vaccine

Trending Articles

  • Revolut takes flight with launch of new airport lounges

  • Grandparents fund university degrees to avoid inheritance tax net

  • Brompton Bicycle sues former adviser for ‘professional negligence’

  • Revolut chatbot goes rogue by charging users to cancel subscription

  • It’s not just Jason Arday, most of sociology is a scam

More from Morning Wire

  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Why did Pinterest choose Oxford Street for its new HQ?

    Opinion
    Gregory Owens and Sadiq Khan, London Mayor, stand smiling in a gallery with various framed images.
  • Fielden: Crafting a modern whisky brand

    Whisky
    Hand holding Fielden Whisky of England Rye Whisky bottle amidst green rye field.
  • Singapore on Thames or the Sick Man of Europe?: The Economics of Brexit Ten Years from the Referendum 

    Opinion
    UK-EU Brexit negotiations meeting with officials discussing trade agreements and policy impacts in a formal conference room
  • New Oxford Economics Study Shows the Social and Economic Impact of Bars

    Business Wire
  • EY and London managing partner fined over £1.3m for audit failure

    Big Four
    EY London headquarters building exterior on a sunny day, showcasing modern architecture in the citys business district
  • Hargreaves Lansdown orders staff back to office

    Investing
    Hargreaves Lansdown financial services office exterior with company logo prominently displayed on modern building façade
  • Mach42 Completes £7M Funding Round, Led by IP Group With Investment From BGF and Foresight Group

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook